Health Minister Mansukh Mandaviya on Friday held a COVID-19 overview assembly with 5 southern states and three union territories and confused that they need to preserve an in depth watch on rising clusters and hotspots within the third wave of the pandemic.
In his assembly along with his counterparts from Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, Telangana, Puducherry, Andaman and Nicobar Islands and Lakshadweep, Mandaviya reiterated that the 5 methods of Test-Track-Treat-Vaccination and adherence to COVID-appropriate conduct Along with efficient monitoring of circumstances, COVID-19 stays vital for administration.
“Adequate and timely testing will help in early detection of infected cases and prevent sudden spike,” Mandaviya instructed them.
With a lot of sufferers in house isolation throughout this increase, Mandaviya requested them to give attention to opening extra teleconsultation facilities as a part of the hub and spoke mannequin. “Telecom centers will not only help us during the pandemic but also for non-Covid medical care,” he mentioned.
On the immunization drive, Mandaviya urged the states and union territories to expedite the tempo of vaccination for the age group of 15-17 years, and people whose second dose is but to return. On testing, he identified that states which have reported low share of RTPCR in Covid-19 testing ought to enhance it.
A day after the assembly, the well being ministry on Thursday highlighted that Karnataka, Kerala, Tamil Nadu and Andhra Pradesh are among the many high 10 states contributing the utmost variety of energetic circumstances to the nationwide Xcovid-19 case.
The ministry had mentioned that Karnataka at the moment accounts for 16.25% of the whole energetic circumstances within the nation. 27 districts within the state are reporting greater than 10% positivity fee, whereas 14 districts of Kerala are reporting greater than 10% positivity fee, it mentioned.
The ministry additionally mentioned that Bangalore Urban and Chennai are among the many districts in South India exhibiting a decline in circumstances and positivity in comparison with the final week, whereas Kerala’s Ernakulam, Kozhikode and Thiruvananthapuram are reporting a lot of circumstances. are.
DCGI permits Bharat Biotech to conduct Phase-3 trial for Nasal COVID Vaccine
The Drug Controller General of India (DCGI), the drug regulator, on Friday accepted Bharat Biotech to conduct phase-3 medical trials of its nasal COVID-19 vaccine. Meanwhile, Bharat Biotech will administer the BBV154 nasal vaccine for each the two-dose major schedule in addition to the booster dose schedule. BBV154 is an adenovirus vector intranasal COVID-19 vaccine. Intranasal vaccination of BBV154 can produce an immune response within the nostril.
,
With inputs from TheIndianEXPRESS
